Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alejandro Lorenzana

Pulmonary Disease Fall River, MA Medical Doctor

NPI 1346326485 CMS profile 333428

203 Plymouth Ave Ste 702, Fall River, MA 02721

Open in the dashboard

General payments

$9,862

491 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alejandro Lorenzana of Fall River, MA is reported in the CMS Open Payments database as having received $9,862 across 491 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,858 127
2024 General $2,053 90
2023 General $1,857 86
2022 General $834 46
2021 General $1,131 60
2020 General $384 23
2019 General $744 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alejandro Lorenzana
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Alejandro Lorenzana were reported at $2,858. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Alejandro Lorenzana Pulmonary Disease median Middle half National median
2019 $744 $377 $109–$1,340 $163
2020 $384 $230 $56–$907 $114
2021 $1,131 $269 $68–$1,072 $132
2022 $834 $390 $100–$1,457 $149
2023 $1,857 $419 $114–$1,659 $160
2024 $2,053 $476 $123–$1,818 $164
2025 $2,858 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,673 98 payments
  2. GlaxoSmithKline, LLC. $1,181 78 payments
  3. Genzyme Corporation $684 35 payments
  4. Novartis Pharmaceuticals Corporation $534 34 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $525 27 payments
  6. Pfizer Inc. $509 28 payments
  7. Amgen Inc. $468 17 payments
  8. Grifols USA, LLC $444 22 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $442 21 payments
  10. Regeneron Healthcare Solutions, Inc. $237 14 payments
  11. Other $2,165 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,828 490 payments
  2. Education $34 1 payment
Products named General payments · program years 2019–2025
  1. FASENRA $1,554 51 payments
  2. TEZSPIRE Respiratory $838 19 payments
  3. DUPIXENT $793 36 payments
  4. NUCALA $678 42 payments
  5. AIRSUPRA $633 16 payments
  6. BREZTRI $497 12 payments
  7. Prolastin-C Liquid $444 22 payments
  8. CUVITRU $410 22 payments
  9. TRELEGY ELLIPTA $403 24 payments
  10. TEZSPIRE Inflammation $390 14 payments
  11. Other $5,317 294 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,773

Median for Pulmonary Disease: 936

Drug cost

$1,277,977

Median for Pulmonary Disease: $487,987

Branded share of claims

68.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 337 $249,439
Xolair Omalizumab Brand 54 $228,624
Tezspire Tezepelumab-Ekko Brand 38 $163,570
Dupixent Pen Dupilumab Brand 26 $104,653
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 144 $101,139
Breo Ellipta Fluticasone/Vilanterol Brand 167 $78,789
Fasenra Pen Benralizumab Brand 12 $66,363
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 24 $62,814
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 73 $40,479
Spiriva Respimat Tiotropium Bromide Brand 38 $24,333

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$115,100

Of which drugs: $628

Medicare patients

493

Average age 73

Services billed

1,934

278 women, 215 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 56%
Arthritis 51%
Ischemic heart disease 48%
Diabetes 43%
Depression 38%
Heart failure 33%
Chronic kidney disease 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 65 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $402
$402 12 —
TEZSPIRE
  • Amgen Inc. $195
  • AstraZeneca Pharmaceuticals LP $152
$347 38 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $210
$210 — —
DUPIXENT
  • GENZYME CORPORATION $172
  • Regeneron Healthcare Solutions, Inc. $25
$197 26 —
XOLAIR
  • Novartis Pharmaceuticals Corporation $134
  • Genentech USA, Inc. $31
$166 54 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

491 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record